Increased platelet activation and fibrinogen in Asian Indians. Potential implications for coronary risk

European Heart Journal

Volumn 19, Issue 5, 1998, Pages 720-726

  Markovitz, Jerome ^a,c   Kulkarni, K ^a   Goldschmidt Clermont, P ^b   Kiefe, C I ^a   Rustagi, P ^a   Sekar, P ^a   Nanda, N ^a  

^a University of Alabama at Birmingham   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

Coronary disease; Fibrinogen; India; Platelet activation

Indexed keywords

FIBRINOGEN; FIBRINOGEN RECEPTOR; INSULIN; LIPID; LIPOPROTEIN A; PADGEM PROTEIN;

ADULT; ARTICLE; BLOOD SAMPLING; CAUCASIAN; CONTROLLED STUDY; CORONARY RISK; DIABETES MELLITUS; FAMILY HISTORY; FEMALE; FIBRINOGEN BLOOD LEVEL; FLOW CYTOMETRY; HUMAN; HUMAN EXPERIMENT; INDIAN; INSULIN BLOOD LEVEL; ISCHEMIC HEART DISEASE; LIPID BLOOD LEVEL; LIPOPROTEIN BLOOD LEVEL; MALE; NORMAL HUMAN; PRIORITY JOURNAL; RACE DIFFERENCE; RISK FACTOR; THROMBOCYTE ACTIVATION; THROMBOCYTE RELEASE REACTION; VENOUS BLOOD;

EID: 0032080738     PISSN: 0195668X     EISSN: None     Source Type: Journal    
DOI: 10.1053/euhj.1997.0800     Document Type: Article

References (36)

1. [1] Chadha S, Radhakrishnan S, Ramachandran K, Kaul U, Gopinath N. Epidemiological study of coronary heart disease in urban population of Delhi. Indian J Med Res 1990; 92: 424-30.
2. [2] Janus ED, Postiglione A, Singh RB, Lewis B. The modernization of Asia: Implications for coronary heart disease. Circulation 1996; 94: 2671-73.
3. [3] Enas EA, Garg A, Davidson MA, Nair VM, Huet BA, Yusuf S. Coronary heart disease and its risk factors in first-generation immigrant Asian Indians to the United States of America. Indian Heart J 1996; 48: 343-53.
4. [4] Enas EA, Mehta J. Malignant coronary artery disease in young Asian Indians: thoughts on pathogenesis, prevention, and therapy. Clin Cardiol 1995; 18: 131-5.
5. [5] McKeigue PM, Miller GJ, Marmot MG. Coronary heart disease in south Asians overseas: a review. J Clin Epidemiol 11989; 42: 597-609.
6. [6] Dhawan J, Bray CL, Warburton R, Ghambhir DS, Morris J. Insulin resistance, high prevalence of diabetes, and cardiovascular risk in immigrant Asians. Genetic or environmental effect?. Br Heart J 1994; 72: 413-21.
7. [7] Bhatnagar D, Anand IS, Durrington PN et al. Coronary risk factors in people from the Indian subcontinent living in West London and their siblings in India. Lancet 1995; 345: 405-9.
8. [8] Stein CE, Fall CHD, Kumaran K, Osmond C, Cox V, Barker DJP. Fetal growth and coronary heart disease in South India. Lancet 1996; 348: 1269-73.
9. [9] Saha N, Heng CK, Mozoomdar BP et al. Racial variation of factor VII activity and antigen levels and their correlates in healthy Chinese and Indians at low and high risk for coronary heart disease. Atherosclerosis 1995; 117: 33-42.
10. [10] Wilhelmsen L, Svardsudd K, Korsan-Bengsten K, Larsson B, Welin L, Tibblin G. Fibrinogen as a risk factor for stroke and myocardial infarction. N Engl J Med 1984; 311: 501-5.
11. [11] Meade TW. Fibrinogen in ischaemic heart disease. Eur Heart J 1995; 16 (Suppl A): 31-4.
12. [12] Shanmugasundaram KR, Srinivas K, Sundaram P et al. Lipid peroxidation, antioxidant defences and red-cell membrane changes in relation to coronary risk index and symptomatic coronary heart disease. J Cardiovasc Risk 1995; 2: 551-61.
13. [13] McKeigue PM, Marmot MG, Syndercombe Court YD, Cottier DE, Rahman S, Riemersma RA. Diabetes, hyperinsulinaemia, and coronary risk factors in Bandladeshis in East London. Br Heart J 1988; 60: 390-6.
14. [14] Chouhan LK, Hajar HA, George T, Pomposiello JC. Clinical and angiographic features of patients from the Indian sub-continent treated with intravenous streptokinase for acute myocardial infarction: Experience in Qatar. Angiology 1992; 43: 641-6.
15. [15] Tofler GH, Brezinski DA, Schafer AI et al. Concurrent morning increase in platelet aggregability and the risk of myocardial infarction and sudden cardiac death. N Engl J Med 1987; 316: 1514-8.
16. [16] Antiplatelet Trailists' Collaboration. Secondary prevention of vascular disease by prolonged antiplatelet treatment. Br Med J 1988; 296: 320-1.
17. [17] Abrams CS, Ellison N, Budzynski AZ, Shattil SJ. Direct detection of activated platelets and platelet-derived micro-particles in humans. Blood 1990; 75: 128-38.
18. [18] Michelson AD. Flow cytometry: a clinical test of platelet function. Blood 1996; 87: 4925-36.
19. [19] Langford EJ, Brown AS, Wainwright RJ et al. Inhibition of platelet activity by S-nitrosoglutathione during coronary angioplasty. Lancet 1994; 344: 1458-60.
20. [20] Kestin AS, Valeri CR, Khuri SF et al. The platelet function defect of cardiopulmonary bypass. Blood 1993; 82: 107-17.
21. [21] Markovitz JH, Roubin GS, Parks JM, Bittner V. Platelet activation and restenosis following coronary stenting: Flow cytometric detection of wound-induced platelet activation. Coronary Artery Disease 1996; 7: 657-65.
22. [22] Weiss EJ, Bray PF, Tayback M et al. A polymorphism of a platelet glycoprotein receptor as an inherited risk factor for coronary thrombosis. N Engl J Med 1996; 334: 1090-4.
23. [23] Markovitz JH, Matthews KA. Platelets and coronary heart disease: Potential psychophysiologic mechanisms. Psychosom Med 1991; 53: 643-68.
24. [24] Cohen S, Kamarck T, Mermelstein R. A global measure of perceived stress. J Health Soc Behav 1983; 24: 385-96.
25. [25] Roysircar Sodowsky G, Plake BS. Psychometric properties of the American-International Relations Scale. Educ Psychol Meas 1991; 51: 207-16.
26. [26] Kulkarni KR, Garber DW, Marcovina SM, Segrest JP. Quantification of cholesterol in all lipoprotein classes by the VAP-II method. J Lipid Res 1994; 35: 159-68.
27. [27] Rosengren A, Wilhelmsen L. Fibrinogen, coronary heart disease and mortality from all causes in smokers and non-smokers. The study of men born in 1933. J Intern Med 1996; 239: 499-507.
28. [28] Cigolini M, Targher G, de Sandre G, Muggeo M, Seidell JC. Plasma fibrinogen in relation to serum insulin, smoking habits and adipose tissue fatty acids in healthy men. Eur J Clin Invest 1994; 24: 126-30.
29. [29] Valek J, Valkova L, Vlasakova Z, Topinka V. Increased fibrinogen levels in the offspring of hypertensive men. Relation with hyperinsulinemia and the metabolic syndrome. Arterioscler Thromb Vasc Biol 1995; 15: 2229-33.
30. [30] Halle M, Berg A, Keul J, Baumstark MW. Association between serum fibrinogen concentrations and HDL and LDL subfraction phenotypes in healthy men. Arterioscler Thromb Vasc Biol 1996; 16: 144-8.
31. [31] Barasch E, Benderly M, Graff E et al. Plasma fibrinogen levels and their correlates in 6457 coronary heart disease patients. The Bezafibrate Infarction Prevention (BIP) Study. J Clin Epidemiol 1995; 48: 757-65.
32. [32] Dotevall A, Johansson S, Wilhelmsen L. Association between fibrinogen and other risk factors for cardiovascular disease in men and women. Results from the Goteborg MONICA survey 1985. Annals Epidemiol 1994; 4: 369-74.
33. [33] Kim HO, Jin Y, Kickler TS, Blackmore K, Kwon OH, Bray PS. Gene frequencies of the five major human platelet antigens in African-American, white, and Korean populations. Transfusion 1995; 35: 863-7.
34. [34] Gerrard JM, Peterson DA. The contribution of platelets to stress-related cardiovascular disease. In: Beamish BE, Singal PK, Dhalla N, eds. Stress and Heart Disease. Boston: Martinus Nijhoff, 1985.
35. [35] Patrono C. Aspirin as an antiplatelet drug. N Engl J Med 1994; 330: 1287-94.
36. [36] Fuster V, Chesebro JH. Aspirin for primary prevention of coronary disease. Eur Heart J 1995; 16 (Suppl E): 16-20.